SAN DIEGO, March 17, 2016 /PRNewswire/ -- Halozyme
Therapeutics (NASDAQ: HALO), a biotechnology company developing
novel oncology and drug-delivery therapies, will present
preclinical data from five studies at the American Association of
Cancer Research (AACR) annual conference next month, including
results from its ongoing research of lead investigational agent,
PEGPH20, and two novel pipeline assets engineered for increased
action in the tumor microenvironment. The AACR annual conference
will take place April 17-20 in
New Orleans.
The new Halozyme research builds on previously published data
demonstrating increased concentration of immune cells,
immunotherapies and chemotherapies in animal models when delivered
in combination with PEGPH20. The studies that will be presented at
AACR show enhanced efficacy of checkpoint inhibitors on tumor
growth inhibition when treated with PEGPH20, further expanding the
company's growing body of preclinical research supporting PEGPH20's
mechanism of action and potential applicability across multiple
types of cancer therapy.
In addition, Halozyme will share data from two novel
Halozyme-developed pipeline assets, an immune checkpoint inhibitor
that targets adenosine in the tumor microenvironment and an
anti-EGFR antibody-drug conjugate.
"We are pleased to share the research of our talented scientists
to build on our study of novel agents targeting the tumor
microenvironment," said Dr. Helen
Torley, president and chief executive officer. "This new
work continues to demonstrate the potential ability of PEGPH20 to
increase tumor growth inhibition and the accumulation of
co-administered therapies across a range of tumor types. We are
also excited to share the first details of two pipeline assets that
we believe hold great promise for the future."
Dr. Torley and Halozyme Chief Scientific Officer, Dr.
Michael LaBarre will host a meeting
for investment professionals during the AACR conference to review
data included in the abstracts. The meeting will take place on
Monday, April 18 at 4 p.m. ET (3 p.m.
CT, 1 p.m. PT). The event will
be webcast live through the "Investors" section of Halozyme's
corporate website and a recording will be made available following
the close of the event.
To access the webcast and additional documents related to the
event, please visit www.halozyme.com approximately fifteen minutes
prior to the start time to register, download and install any
necessary audio software. The live event may be accessed by calling
(877) 410-5657 (domestic callers) or (334) 323-7224 (international
callers) using passcode 987221. A telephone replay will be
available after the event by dialing (877) 919-4059 (domestic
callers) or (334) 323-0140 (international callers) using replay
passcode 13259083.
Halozyme's AACR abstracts include:
- PEGylated recombinant hyaluronidase PH20 enhances pemetrexed
antitumor efficacy in a human non-small cell lung cancer model,
Sun., April 17, 1-5 p.m. CT
- Preclinical evaluation of a next-generation EGFR targeting
antibody-drug conjugate that promotes regression in KRAS and BRAF
tumors, Mon., April 18, 8 a.m. – noon
CT
- Enzymatic depletion of adenosine by PEGylated, engineered
adenosine deaminase 2 (PEG-ADA2): a novel immunotherapeutic
approach to treat solid tumors, Mon., April
18, 8 a.m. – noon CT
- PEGPH20 increases the anticancer activity of standard
chemotherapy combinations, vincristine (VIN) and D actinomycin
(DACT), in a Wilms xenograft model, Mon.,
April 18, 1-5 p.m. CT
- PEGylated recombinant hyaluronidase PH20 (PEGPH20) enhances
checkpoint inhibitor efficacy in syngeneic mouse models of cancer,
Weds., April 20, 8 a.m. – noon
CT
About PEGPH20
PEGPH20 is an investigational PEGylated
form of Halozyme's proprietary recombinant human hyaluronidase
under clinical development for the potential systemic treatment of
tumors that accumulate hyaluronan. FDA granted orphan drug
designation to PEGPH20 for treatment of pancreatic cancer and fast
track for PEGPH20 in combination with gemcitabine and
nab-paclitaxel for the treatment of metastatic pancreatic
cancer.
Additionally, the European Commission, acting on the
recommendation from the Committee for Orphan Medicinal Products of
the European Medicines Agency, designated investigational drug
PEGPH20 an orphan medicinal product for the treatment of pancreatic
cancer.
About Halozyme
Halozyme Therapeutics is a
biotechnology company focused on developing and commercializing
novel oncology therapies that target the tumor microenvironment.
Halozyme's lead proprietary program, investigational drug PEGPH20,
applies a unique approach to targeting solid tumors, allowing
increased access of co-administered cancer drug therapies to the
tumor in animal models. PEGPH20 is currently in development for
metastatic pancreatic cancer, non-small cell lung cancer, gastric
cancer, metastatic breast cancer and has potential across
additional cancers in combination with different types of cancer
therapies. In addition to its proprietary product portfolio,
Halozyme has established value-driving partnerships with leading
pharmaceutical companies including Roche, Baxalta, Pfizer, Janssen,
AbbVie and Lilly for its ENHANZE™ drug delivery platform. Halozyme
is headquartered in San Diego. For
more information visit www.halozyme.com.
Safe Harbor Statement
In addition to historical
information, the statements set forth above include forward-looking
statements (including, without limitation, statements concerning
the possible activity, benefits and attributes of PEGPH20, the
possible method of action of PEGPH20, its potential application to
improve cancer therapies and statements concerning future actions
and clinical trials relating to the development of PEGPH20) that
involve risk and uncertainties that could cause actual results to
differ materially from those in the forward-looking statements. The
forward-looking statements are typically, but not always,
identified through use of the words "believe," "enable," "may,"
"will," "could," "intends," "estimate," "anticipate," "plan,"
"predict," "probable," "potential," "possible," "should,"
"continue," and other words of similar meaning. Actual results
could differ materially from the expectations contained in
forward-looking statements as a result of several factors,
including unexpected expenditures and costs, unexpected results or
delays in development and regulatory review, regulatory approval
requirements, unexpected adverse events and competitive conditions.
These and other factors that may result in differences are
discussed in greater detail in the Company's Annual Report on Form
10-K recently filed with the Securities and Exchange
Commission.
Contacts:
Jim
Mazzola
858-704-8122
ir@halozyme.com
Chris Burton
858-704-8352
ir@halozyme.com
Logo -
http://photos.prnewswire.com/prnh/20100302/LA63139LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/halozyme-to-present-data-from-five-preclinical-studies-at-american-association-of-cancer-research-annual-conference-300237488.html
SOURCE Halozyme Therapeutics, Inc.